Abstract
Objective: The purpose of this meta-analysis was to evaluate the inclusivity of diverse groups in laryngeal cancer trials conducted in the U.S. from 2018 to 2023.
Data Sources: Pubmed (MEDLINE), Embase (Elsevier)
Review Methods: Our systematic review and meta-analysis assessed population diversity and representation in laryngeal cancer clinical trials using the Clinical Diversity Rating (CDR) framework developed by Agboola and Wright.1 We searched Embase (Elsevier) and MEDLINE (PubMed) to identify relevant clinical trials conducted in the U.S. between January 1, 2018, and December 31, 2023. Two masked authors independently extracted demographic data from eligible trials. Representation was assessed using the participation-to-disease representation ratio (PDRR), which provides an overall rating of "good," "fair," or "poor" based on the concordance between sample demographics and disease population for laryngeal cancer.
Results: From an initial 203 records, we retained 8 trials in our final sample of which 62.5% involved pharmaceuticals, 25% were surgical, and 12.5% involved behavioral interventions. Data on sex, age, and race/ethnicity showed poor or fair representation, with only one trial receiving a "good" rating for sex diversity. PDRR revealed a significant overrepresentation of White participants (87.5% of trials) and an underrepresentation of Asian, Black, and Hispanic groups, with some trials showing statistically significant inequities.
Data Sources: Pubmed (MEDLINE), Embase (Elsevier)
Review Methods: Our systematic review and meta-analysis assessed population diversity and representation in laryngeal cancer clinical trials using the Clinical Diversity Rating (CDR) framework developed by Agboola and Wright.1 We searched Embase (Elsevier) and MEDLINE (PubMed) to identify relevant clinical trials conducted in the U.S. between January 1, 2018, and December 31, 2023. Two masked authors independently extracted demographic data from eligible trials. Representation was assessed using the participation-to-disease representation ratio (PDRR), which provides an overall rating of "good," "fair," or "poor" based on the concordance between sample demographics and disease population for laryngeal cancer.
Results: From an initial 203 records, we retained 8 trials in our final sample of which 62.5% involved pharmaceuticals, 25% were surgical, and 12.5% involved behavioral interventions. Data on sex, age, and race/ethnicity showed poor or fair representation, with only one trial receiving a "good" rating for sex diversity. PDRR revealed a significant overrepresentation of White participants (87.5% of trials) and an underrepresentation of Asian, Black, and Hispanic groups, with some trials showing statistically significant inequities.
Original language | American English |
---|---|
Pages | 24 |
State | Published - 13 Sep 2024 |
Event | Symposium on Tribal and Rural Innovation in Disparities and Equity for Health - Tahlequah, United States Duration: 13 Sep 2024 → 13 Sep 2024 |
Conference
Conference | Symposium on Tribal and Rural Innovation in Disparities and Equity for Health |
---|---|
Country/Territory | United States |
City | Tahlequah |
Period | 13/09/24 → 13/09/24 |